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Introduction
Precise control over gene expression is an important issue both in gene therapy protocols and for the exploration of gene function. One of the most elegant regulatable promoter systems in use today, developed by Bujard and coworkers, involves the E. coli tetracycline (tc) repressor fused with the C-terminal domain of eukaryotic transcriptional activator VP16. This tetracycline-regulatable transcription factor (tTA) specifically trans-activates artificial 'minimal' promoters carrying multiple tc operator sites (tc-Op [1] [2] [3] [4] [5] ). Adding tc to the system reversibly inhibits binding of tTA to promoter DNA and blocks gene expression. This switch has been used in this configuration in transgenic mice, 2, [6] [7] [8] [9] [10] [11] [12] [13] [14] plants, [15] [16] [17] [18] [19] recombinant adenovirus, 20 herpes simplex virus 21 and retroviruses. [22] [23] [24] A variation of the original system involves a tTA derivative that carries four point mutations, rtTA, which does not trans-activate in the default state, but requires a tc-like compound (doxycycline or anhydrotetracycline) for gene activation. 5 Recently a tc-derivative chemical was discovered that acts as an agonist on the original tTA activator. 25 Finally, a fusion of the bacterial tc repressor with a transcriptional silencer domain (KRAB) has been used to reversibly silence an active promoter. 26 We have sought to exploit maximally the modular character of the tc-regulatable system in order to obtain highly controllable transgene expression. As a vehicle for gene introduction we have chosen adenovirus, as this virus infects many different host cell types, does not integrate into the host genome, and is currently used in some human gene therapy trials. 27 By adenovirus-mediated gene transfer and expression of the tc-regulatable activator (tTA) into transgenic animals that carry a transgene under tc-Op promoter control, topical and tc-regulatable gene expression can be achieved. Conversely, we have injected adenovirus carrying a reporter gene under the tc-Op promoter into transgenic mice expressing tTA under a muscle-specific promoter to achieve topical, tissue-specific and tetracycline-regulatable gene expression.
Results
Gene activation by interbreeding of two transgenic mouse lines The expression constructs used in this work are schematically represented in Figure 1 . Transgenic mice were constructed expressing tTA (the tc-regulatable transactivator) under the control of the human muscle-specific creatine kinase promoter 28 ( Figure 1b) . As expected, all lineages examined strongly expressed tTA mRNA in striated muscle (data for two animals are shown in Figure 2a) ; weak expression was also detected in heart and lung. In order to test if these mice produced functional tTA, we had constructed a second transgenic mouse line that encoded a fusion protein with the extra- ) and the Fc portion of human IgG1. This cDNA was placed under the control of a minimal promoter carrying seven palindromic binding sites for the tc-regulatable tTA (Figure 1d ). The rationale for the chimerical trkB/Fc construct was to produce a stable, soluble fusion protein (a 'receptor-body') that has the potential to bind and inactivate serum BDNF, the ligand of trkB.
The two mouse lines were crossed to generate doubletransgenic mice, and these were analyzed by Northern blot for trkB/Fc mRNA expression in various organs. As shown in Figure 2b , strong expression of trkB/Fc mRNA was found in skeletal muscle in double-transgenic, but not in single-transgenic animals (panels 1 and 5 versus panels 2-4, solid arrow). Mirroring the results shown in Figure 2a , weak signals were seen in the heart and lungs as well. In all animals, a second, faster migrating band is seen in the brain; this is probably endogenous mouse trkB mRNA that cross-hybridized with the rat trkB cDNA probe 30 (open arrow). In order to see if the double-transgenic animals produced full-length trkB/Fc fusion protein, we analyzed the serum by SDS-PAGE and Western blot. TrkB/Fc was detected using antisera directed against Fc (Figure 2c . Steady-state serum trkB/Fc production as measured by ELISA varied approximately three-fold (between 13 and 38 g/ml) among different doubletransgenic animals; this variability was seen even when lineages of the same transgenic founder were used (data not shown).
In order to study gene on/off switching in these double-transgenic animals, the antibiotic tc was administered in drinking water. Tc binds the prokaryotic tetracyclinerepressor domain in tTA and inhibits tTA's promoter binding and eukaryotic trans-activation. As expected, trkB/Fc levels began to drop within a few days of tc administration ( Figure 3 ) until it bottomed out at a few per cent of the original levels after about 40-60 days. At day 82, tc-free water given again to the animals, and serum trkB/Fc began to rise. We suspect that the rise was submaximal due to residual levels of tc accumulated in bone and teeth. 31 At 70 days after withdrawal of tc serum trkB/Fc had reached about 75% of the maximal levels seen at day 0. It should be emphasized that the 100% serum trkB/Fc levels at day 0 had resulted from lifelong accumulation in the animals.
Recombinant adenovirus gene activation by mouse tTA
In order to test if mouse transgenic tTA was able to transactivate recombinant adenoviral genes, we constructed two replication-defective recombinant adenovirus vectors. One vector carried reporter luciferase cDNA under the minimal (enhancer-less) CMV promoter plus tc-operators ( Figure 1c ). The second, control recombinant adenovirus vector had tTA cDNA driven by the CMV promoter/enhancer ( Figure 1a ). The viruses were injected into the hippocampus or calf muscle of PmcktTA transgenic, or control mice. Five days after infection the animals were killed and tissues where the virus had been injected analyzed for luciferase activity. As shown in Figure 4 , co-injection of the two recombinant adenoviruses gave a strong signal in both tissues tested ( tTA- 32 or CMV-enhancer activity (which drives transcription of tTA).
Mouse gene activation by recombinant adenovirus vector carrying tTA Finally, we set up the reverse situation with adenovirusderived tTA activating mouse gene expression. A group of four mice transgenic for O 7 -trkB/Fc was injected i.m. with a recombinant adenovirus expressing tTA under the CMV promoter/enhancer. As shown in Figure 5 the animals rapidly started producing serum trkB/Fc, as measured by ELISA, with levels going up until day 8. This was followed by a drop in serum trkB/Fc between day 8 and day 15 to near-basal levels at day 30. This timecourse is in agreement with earlier reports where ␤-gal or luciferase producing adenovirus was introduced into rat myocardium or mouse lung epithelium, with signals disappearing after 21 or 14 days. These studies have also clearly shown that this time-course is shaped predominantly by the host's immune response to the virus. 33, 34 More recently, so-called 'second generation' E1/E4-deleted adenovirus vectors have been contructed that show extended gene expression in immunocompetent mice. 35 Wild-type mice (C57) injected with tTA recombinant adenovirus, or non-injected O 7 -trkB/Fc mice did not show measurable (Ͻ0.8 ng/l) serum trkB/Fc at any time-point, supporting the specificity of transcriptional control (data not shown).
Discussion
The work described here shows that the two components of the tetracycline-controllable genetic switch can be encoded by an animal's genome (Figure 2b (Figure 4) . The usefulness of a regulatable switch in gene therapy protocols is well-appreciated since it would allow easy control over therapeutic gene expression (eg insulin secretion) by administration of tetracycline or another orally available drug. But in addition to this there is the binary character of the switch, whose components can be separated and integrated into different genomes, as demonstrated in this work. This latter property presents advantages both in gene therapy protocols and for the study of gene function, as discussed in more detail below.
For several reasons the modular characteristic of the regulatable tc system is an important asset when implemented in gene therapy protocols. For vectors with limited capacity for extraneous sequences, such as adenovirus and adeno-associated virus (AAV), the tTA and therapeutic gene load can be divided and the viruses administered as a mix. The strength of the dose and differential administration of two or more therapeutic genes can, to some extent, be controlled by varying the ratio of viruses in the mixture. In most gene therapy protocols, integration of viral DNA sequences into the genome is not desirable. Partitioning the viral genes over two vectors greatly diminishes the risk that a single host cell will integrate both units of the tc system in its genome. The probability that a cell is infected with all different viruses of a mixture decreases exponentially with the virus concentration. This is important if one wishes to localize gene delivery to the site of infection and limit systemic side-effects. A final reason to keep the different components genetically separated is that the minimal tc-regulatable promoter is sensitive to cis-acting enhancers, especially to the CMV enhancers often used to drive tTA transcription. 36 The modular structure of the tc-system is also very useful for the study of gene function. One obvious practical point is that the system is combinatorial; the same construct conferring, eg, specific expression of tTA in liver can be used in combination with a variety of target genes. An important application is the study of gene function by regulatable inhibition, as opposed to irreversible gene mutation. Although the knockout animal model ensures
Figure 4 Activation of recombinant adenovirus gene expression induced by mouse tTA. Luciferase activity in hippocampus (left panel) or striated muscle (right panel) in mice transgenic (tg) for Pmck-tTA, or wild-type mice (wt). Five days before death the animals were injected in the hippocampus or in the calf muscle with recombinant adenovirus expressing luciferase under the tc-operator (L), adenovirus expressing tTA under the CMV promoter/enhancer (A), control virus expressing ␤-galactosidase (B) or with saline (S, Hank's buffer). Some animals were given tc from 15 days before the virus injections (tc). Data are expressed as mean ± standard error (n = 2-8).

Figure 5 Mouse gene activation induced by recombinant adenovirus tTA. Mice transgenic for O 7 -trkB/Fc were intramuscularly injected on day 0 with recombinant adenovirus expressing tTA controlled by the CMV promoter/enhancer. Serum trkB/Fc was measured on different days thereafter by ELISA. Data are expressed as mean ± standard error (n = 4).
that no residual gene activity exists, this model suffers from multiple drawbacks. 37 An animal developing without one of its genes (if it survives at all) is not in a situation which is similar to drug-induced gene inhibition at the adult stage. Therefore, the about 50% of genes that are lethal when tested as a knockout 38, 39 should not automatically be dismissed as drug targets. The tc-regulatable system is well-suited to explore these important issues.
We have shown here that the components of the tcregulatable system can be delivered by any combination of adenovirus vector and animal transgene: tTA and its target gene may both be transgenic, tTA may be encoded by the adenovirus vector and its target as a transgene or vice versa and, finally, both components may be encoded by separate recombinant adenoviruses. In all cases we could demonstrate that the system worked properly and was tc regulatable, although the kinetics of gene activation and repression varied.
Our work clearly validates the flexible and modular character of the tc-regulatable system, but it also reveals a number of practical limitations. Tissue-specific targeting is only as precise as the chosen promoter allows for. In our case, using the mck promoter we found low levels of gene activity in organs (heart, lung) that do not contain striated muscle tissue. Also, promoters that confer tissue specificity are often long (3.5 kbp for the mck gene), which may hamper their packaging into some types of recombinant viruses.
When constructing transgenic mice based on the tc system it may take a long time to establish which line(s) correctly express their transgenes. A shortcut is to establish primary ear fibroblast cultures which can be transfected with reporter constructs. Thus, we were able to identify transgenic founder lines carrying an active O 7 -trkB/Fc construct early by transfecting ear fibroblasts with tTA-expressing plasmid and measuring supernatant trkB/Fc fusion protein by ELISA (data not shown).
The speed of up-and down-regulation of gene activity by administration or withdrawal of tc is dependent on the half-lives of the gene of interest's mRNA and its translation product, the half-life of tc and, presumably, the amount of tc accumulated by the animal over time. Among these, retention of tc in whole animals may be the most critical factor. The in vivo situation contrasts sharply with the fast tTA re-activation seen when removing tc from cell cultures. 3, 36 This retention is caused by accumulation of tc in solid tissues and the relatively long in vivo half-lives of tc (4-12 h) and doxycycline (12-24 h ). 31 The use of tc derivatives such as anhydro-tc 2,40 or doxycycline 5, 13 which are active at lower concentrations, or of the tc antagonist 25 may accelerate re-activation of tTA. However, these compounds are more expensive than tc or not (yet) commercially available. Another way to enhance re-induction would be to use a system based on rtTA. 5 By contrast, we achieved relatively fast off-switching in double-transgenic mice by administration of tc (Figure 3) . Efficient, fast induction of gene activity was seen by local virus injection ( Figure 5 ). The ultimate choice of distribution of tc-regulatable components over virus and transgenic animal depends on the precise requirements of where, when and with what kinetics the foreign gene is to be expressed.
We conclude that the tc-regulatable system has properties that will enhance the efficacy and safety of genetic therapies. Combined with tools established for gene inhibition (antisense, 41 receptor-bodies, dominant negative transcription factors 42 and the like 36 ) the tc system is also ideally suited to face the functional exploration of the upcoming plethora of candidate genes that are being identified by genome sequencing projects.
Materials and methods
Construction of plasmid and recombinant adenoviruses vectors
Ad-CMV-tTA: The tTA cDNA was PCR amplified from plasmid pUHG15-1 3 with oligonucleotides ATA GGA TCC AAG ACA CCG GGA CCG ATC CAG CCT C and ACC CTG AAG TTC TCA GTC TAG AGG ATC CTC G. The fragment was BamHI digested and cloned into the BamHI site of shuttle plasmid pAd-CMV-B (a gift from I Kovesdi, GenVec, Rockville, MD, USA).
Ad-Otc-luciferase: This virus has the minimal CMV promoter with seven operator sites (474 bp XhoI-XbaI fragment of pUHG10-3) 43 linked to the luciferase gene (1689 bp HindIII-XbaI fragment from pGL3-Basic (Promega, Madison, WI, USA)) and an SV40 splice and polyadenylation site. The recombinant virus was created in E. coli and then grown and amplified in HEK 293 cells. Like the other viruses in this study the O 7 -luc expression cassette replaces the E1 region of IN340.
Ad-Otc-␤-gal: The ␤-gal cDNA from pCH110 (Pharmacia, Uppsala, Sweden) was cut out using HindIII and BamHI, blunted, and inserted into the BamHI site of pAd-CMV-B. All PCR-amplified fragments and their junctions were controlled by DNA sequencing.
The linearized shuttle vector was cotransfected in HEK 293 cells together with E1/E3-deleted viral DNA (IN340). 44 The resulting virus was plaque-purified and expanded on 293 cells. 45 Adenovirus preparations were purified by two sequential centrifugations on CsCl density gradients, desalted on G-50 Sephadex columns (Boehringer, Mannheim, Germany; now Boehringer-Roche), reconstituted in Hank's balanced salt solution (HBSS; GIBCO-BRL, Life Sciences, Basel, Switzerland), divided into aliquots and stored at −80°C. Viral titers were determined on 293 cells both by plaque assay (p.f.u.) and by focus-forming unit assay (f.f.u.) using monoclonal anti-adenovirus antibodies (Biodesign, Kennebunk, ME, USA) and an anti-mouse IgG secondary antibody conjugated to fluorescein isothiocyanate (FITC).
Injection of recombinant adenoviruses
Intramuscular injections of recombinant adenoviruses diluted at 10 6 p.f.u./l in 50 l Hank's solutions were performed in the striated muscle of the mouse rear paws. The mice were anesthetized with alothane (1%) and injected in both distal and proximal muscles using a disposable 1 ml syringe.
Micro-injections of 2 l of recombinant adenovirus into the hippocampus were performed using a Kopf stereotactic apparatus for small animals. An injection unit made by a 30-gauge stainless steel needle connected with a P10 tubing to a Hamilton syringe was used. Stereotactic coordinates for the injection site were calculated from bregma as follows: A, −2.30 mm; L, 2.00 mm; L, 2.00 mm; V, −3.5 mm; as described. 46 For stereotactic surgery the mice were anesthetized with alothane (1%). The experiment was performed according to the NIH guidelines for Animal Care and was approved by the Office Veterinaire Cantonale of Geneva, Switzerland. After surgery, all animals were placed in one per cage and maintained under controlled environmental conditions in AERF (Neuillysur-Marne, France) insulators until the day of death. Animals were killed using a lethal dose of pentobarbital followed by decapitation. Where indicated, animals were given tc (Sigma, St Louis, MO, USA) in drinking water at 0.5 g/ml plus 1% sucrose 15 days before virus infection.
Transgenic mice
Pmck-tTA: The parent vector (a gift from Dr Hauschka, Johns Hopkins University, Baltimore, MD, USA) was pNASS␤ (ClonTech, Palo Alto, CA, USA) carrying the 3.3 kbp human muscle-specific creatine promoter as an EcoRI-BstE2 fragment from p-3300mckCAT 28 in its EcoRI-XhoI sites. The tTA cDNA was EcoRI-BamHI excised from plasmid 383bp-tet 47 (a pUHG15-1 derivative). The vector was NotI-cut, and the insert and vector were Klenow-blunted for ligation. The 4.9 kbp fragment for mouse transgene production was obtained after digestion with EcoRI, PvuI and HindIII, and purified on agarose gel using DEAE-membrane. 48 P-Otc-TrkB/Fc: The TrkB/Fc cDNA (2.0 kb) encoded the rat TrkB ectodomain fused with the Fc portion of the human IgG1 just upstream to the hinge region of the Fc domain, cloned as an XhoI-NotI fragment in pCMX (obtained from Dr G Yancopoulos, Regeneron Inc., Tarrytown, NY, USA). This fragment was blunt-cloned into the pUHG10-3 XbaI site. The 3233 bp fragment for mouse transgene production was obtained after digestion with BglII, PvuI and XhoI. Generation of transgenic mice was at the Centre for Genome Research, Edinburgh, UK in [CBA/CaxC57Bl/6] × [CBA/Ca × C57Bl/6] F2 mice. Founders were crossed with C57Bl/6. Administration of tc was in drinking water at 0.5 g/ml plus 1% sucrose, refreshed bi-weekly. Plasmids pUHG15-1 and pUHG10-3 were obtained from Dr H Bujard (University of Heidelberg, Germany).
Northern blot hybridizations
Organ and tissue was snap-frozen in N 2 (l), crushed using a mortar and pestle and RNA was isolated using Trizol (GIBCO-BRL) according to the manufacturer's instructions; 20 g per lane was fractionated on 1% agarose gels containing 2.2 m formaldehyde and blotted on to nylon membrane filters (Hybond-N + ; Amersham, Bucks, UK). Transfer efficiency was controlled by methylene blue staining. 48 Gel-purified cDNA fragments were radiolabelled using ␣-32 P dCTP (Amersham) and HighPrime (Boehringer Mannheim) and hybridized at 1-2 × 10 6 c.p.m./ml in 50% formamide as described. 49 The probe used for Figure 2a was a 1.2 kbp XbaI fragment from plasmid Pmck-tTA. The probe for Figure 2b was the 1.1 kbp EcoRI/PvuII fragment from P-Otc-TrkB/Fc.
PAGE, Western blotting and detection of trkB/Fc
Samples were run on an 8-16% PAGE-SDS gel (Novex, San Diego, CA, USA) for 1.5-2 h at 125 V, and transferred to nitrocellulose for 1.5 h at 200 mA, cooled in ice, using an electrotransfer apparatus (BioRad, Hercules, CA, USA). The blot was colored with Ponceau Red to check for transfer, 48 rinsed in PBS, blocked for 2 h in 5% BSA, 50 mm Tris-Cl pH 8 and incubated for 1 h with 0.3 g/ml anti-hIgG1-alkaline phosphatase (Southern Biotechnology, Birmingham, AL, USA). Staining was in 1 mg/ml 5′Br-4-Cl-3-indolyl phosphate NitroBlue Tetrazolium (Sigma) at room temperature, followed by incubation for 2 min in PBS/20 mm EDTA and photographed.
The same blot was blocked with BSA and incubated for 1.5 h in 2.5 g/ml rabbit anti-mouse trkB (ectodomain), followed by 1.5 h incubation in goat anti-rabbit IgG(H and L)-HRP (BioRad; 1000 diluted). The blot was developed using chemoluminescence reagents (ECL reagents RPN 2106; Amersham) according to the manufacturer's instructions and exposed for 5 s.
ELISA
Microtiter plates (Nunc, Life Technologies, Rochester, NY, USA) were coated overnight with goat anti-human IgG (␥-chain specific; Sigma I-3382) at 2 g/ml in PBS 48 and blocked in 1% BSA/PBS. Serum was incubated at 500-, 1000-or 1500-fold dilutions for Figure 3 and at 10-fold dilution for the data in Figure 5 , for 2 h at 37°C. This was followed by incubation for 1 h at 37°C with alkaline phosphatase-conjugated goat anti-human IgG antibody (␥-chain specific; Sigma A-3187) at 1:1000 dilution. Detection was with 1 mg/ml pNpp substrate (Sigma FAST tablets), and read with a 405 nm plate reader. The detection limit was 0.8 ng/ml.
Luciferase assay
Upon killing the animals, the entire area of virus injection was excised. The tissue was taken up in 1 (muscle) or 0.3 (hippocampus) ml buffer, 25 freeze-thawed three times, homogenized and assayed as described, 25 except that luminosity was read for 30 s. Values were corrected for background (buffer), normalized for the volume in which the tissue was suspended and averaged per injection site.
